A potential novel pathological implication of serum soluble triggering receptor expressed on myeloid cell 2 in insulin resistance in a general Japanese population: The Hisayama study

Masashi Tanaka, Takanori Honda, Hajime Yamakage, Jun Hata, Daigo Yoshida, Yoichiro Hirakawa, Mao Shibata, Takayuki Inoue, Toru Kusakabe, Noriko Satoh-Asahara, Toshiharu Ninomiya

Research output: Contribution to journalArticle

Abstract

Aims: No cohort study has examined the pathological significance of triggering receptor expressed on myeloid cell 2 (TREM2), a cell surface receptor expressed on myeloid lineage cells, and its soluble form, sTREM2, in insulin resistance in a general population. Methods: A total of 2742 community-dwelling Japanese individuals aged ≥40 years were divided into 4 groups according to the serum sTREM2 concentration quartiles. We examined the cross-sectional association of sTREM2 levels with anthropometric parameters and the homeostasis model assessment of insulin resistance (HOMA-IR). Results: The median sTREM2 concentrations was 255.6 (interquartile range, 162.5–419.2) pg/mL. In multivariate analyses, waist circumference and fat mass index increased with elevating sTREM2 levels (P for trend: <0.001 and 0.02, respectively), but there was no significant association between sTREM2 levels and body mass index and fat-free mass index. Among the subjects without taking antidiabetic medications (n = 2610), greater sTREM2 levels were associated with higher HOMA-IR (P for trend <0.001) even after adjusting for waist circumference, fat mass index, and high-sensitivity C-reactive protein. Conclusions: Our findings suggest that serum sTREM2 had novel pathological roles in insulin resistance, while obesity and inflammation had no substantial effects on the relationship between sTREM2 and insulin resistance in this cohort.

Original languageEnglish
Pages (from-to)225-232
Number of pages8
JournalDiabetes Research and Clinical Practice
Volume146
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Myeloid Cells
Insulin Resistance
Serum
Population
Fats
Waist Circumference
Homeostasis
Independent Living
Cell Surface Receptors
Hypoglycemic Agents
C-Reactive Protein
Body Mass Index
Cohort Studies
Multivariate Analysis
Obesity
Inflammation

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{f873bcbb011240c79d97b3d97ed926d3,
title = "A potential novel pathological implication of serum soluble triggering receptor expressed on myeloid cell 2 in insulin resistance in a general Japanese population: The Hisayama study",
abstract = "Aims: No cohort study has examined the pathological significance of triggering receptor expressed on myeloid cell 2 (TREM2), a cell surface receptor expressed on myeloid lineage cells, and its soluble form, sTREM2, in insulin resistance in a general population. Methods: A total of 2742 community-dwelling Japanese individuals aged ≥40 years were divided into 4 groups according to the serum sTREM2 concentration quartiles. We examined the cross-sectional association of sTREM2 levels with anthropometric parameters and the homeostasis model assessment of insulin resistance (HOMA-IR). Results: The median sTREM2 concentrations was 255.6 (interquartile range, 162.5–419.2) pg/mL. In multivariate analyses, waist circumference and fat mass index increased with elevating sTREM2 levels (P for trend: <0.001 and 0.02, respectively), but there was no significant association between sTREM2 levels and body mass index and fat-free mass index. Among the subjects without taking antidiabetic medications (n = 2610), greater sTREM2 levels were associated with higher HOMA-IR (P for trend <0.001) even after adjusting for waist circumference, fat mass index, and high-sensitivity C-reactive protein. Conclusions: Our findings suggest that serum sTREM2 had novel pathological roles in insulin resistance, while obesity and inflammation had no substantial effects on the relationship between sTREM2 and insulin resistance in this cohort.",
author = "Masashi Tanaka and Takanori Honda and Hajime Yamakage and Jun Hata and Daigo Yoshida and Yoichiro Hirakawa and Mao Shibata and Takayuki Inoue and Toru Kusakabe and Noriko Satoh-Asahara and Toshiharu Ninomiya",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.diabres.2018.10.007",
language = "English",
volume = "146",
pages = "225--232",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - A potential novel pathological implication of serum soluble triggering receptor expressed on myeloid cell 2 in insulin resistance in a general Japanese population

T2 - The Hisayama study

AU - Tanaka, Masashi

AU - Honda, Takanori

AU - Yamakage, Hajime

AU - Hata, Jun

AU - Yoshida, Daigo

AU - Hirakawa, Yoichiro

AU - Shibata, Mao

AU - Inoue, Takayuki

AU - Kusakabe, Toru

AU - Satoh-Asahara, Noriko

AU - Ninomiya, Toshiharu

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Aims: No cohort study has examined the pathological significance of triggering receptor expressed on myeloid cell 2 (TREM2), a cell surface receptor expressed on myeloid lineage cells, and its soluble form, sTREM2, in insulin resistance in a general population. Methods: A total of 2742 community-dwelling Japanese individuals aged ≥40 years were divided into 4 groups according to the serum sTREM2 concentration quartiles. We examined the cross-sectional association of sTREM2 levels with anthropometric parameters and the homeostasis model assessment of insulin resistance (HOMA-IR). Results: The median sTREM2 concentrations was 255.6 (interquartile range, 162.5–419.2) pg/mL. In multivariate analyses, waist circumference and fat mass index increased with elevating sTREM2 levels (P for trend: <0.001 and 0.02, respectively), but there was no significant association between sTREM2 levels and body mass index and fat-free mass index. Among the subjects without taking antidiabetic medications (n = 2610), greater sTREM2 levels were associated with higher HOMA-IR (P for trend <0.001) even after adjusting for waist circumference, fat mass index, and high-sensitivity C-reactive protein. Conclusions: Our findings suggest that serum sTREM2 had novel pathological roles in insulin resistance, while obesity and inflammation had no substantial effects on the relationship between sTREM2 and insulin resistance in this cohort.

AB - Aims: No cohort study has examined the pathological significance of triggering receptor expressed on myeloid cell 2 (TREM2), a cell surface receptor expressed on myeloid lineage cells, and its soluble form, sTREM2, in insulin resistance in a general population. Methods: A total of 2742 community-dwelling Japanese individuals aged ≥40 years were divided into 4 groups according to the serum sTREM2 concentration quartiles. We examined the cross-sectional association of sTREM2 levels with anthropometric parameters and the homeostasis model assessment of insulin resistance (HOMA-IR). Results: The median sTREM2 concentrations was 255.6 (interquartile range, 162.5–419.2) pg/mL. In multivariate analyses, waist circumference and fat mass index increased with elevating sTREM2 levels (P for trend: <0.001 and 0.02, respectively), but there was no significant association between sTREM2 levels and body mass index and fat-free mass index. Among the subjects without taking antidiabetic medications (n = 2610), greater sTREM2 levels were associated with higher HOMA-IR (P for trend <0.001) even after adjusting for waist circumference, fat mass index, and high-sensitivity C-reactive protein. Conclusions: Our findings suggest that serum sTREM2 had novel pathological roles in insulin resistance, while obesity and inflammation had no substantial effects on the relationship between sTREM2 and insulin resistance in this cohort.

UR - http://www.scopus.com/inward/record.url?scp=85056246723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056246723&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2018.10.007

DO - 10.1016/j.diabres.2018.10.007

M3 - Article

VL - 146

SP - 225

EP - 232

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

ER -